Sciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is not done yet.
June 12, 2026 05:00 AM EDTUpdated 10:32 AM
DealsChinaGLP-1 drugs
Sciwind has two Western partners for its obesity drug, but is open to more
Elizabeth Cairns
Senior biopharma journalist
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases — Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
Drugmakers race to find a place in the next wave of obesity drugs
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss…
Top scientists from have suggested that GLP-1s could have broader effects than just tackling obesity and diabetes.
In China, over 60 late-stage drugs are undergoing clinical trials, and may compete with those from incumbents Novo Nordisk and…
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how…
For Novo Nordisk, the launch of the company’s highly anticipated Wegovy pill at the start of the year—representing the first oral…
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for…
